JAGSNPHARM — Jagsonpal Pharmaceuticals Income Statement
0.000.00%
- IN₹9.87bn
- IN₹8.48bn
- IN₹2.09bn
- 83
- 17
- 53
- 50
Annual income statement for Jagsonpal Pharmaceuticals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | R2022 March 31st | 2023 March 31st | 2024 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | IAS | IAS | IAS | IAS | — |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1,586 | 1,879 | 2,176 | 2,367 | 2,087 |
Cost of Revenue | |||||
Gross Profit | 1,024 | 1,072 | 1,278 | 1,344 | 1,154 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 1,512 | 1,700 | 1,931 | 2,065 | 1,873 |
Operating Profit | 74 | 180 | 245 | 302 | 214 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 94.1 | 219 | 266 | 348 | 299 |
Provision for Income Taxes | |||||
Net Income After Taxes | 78.7 | 171 | 189 | 267 | 225 |
Net Income Before Extraordinary Items | |||||
Net Income | 78.7 | 171 | 189 | 267 | 225 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 78.7 | 171 | 189 | 267 | 225 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 3 | 6.51 | 7.19 | 11.2 | 8.46 |
Dividends per Share |